2 weeks Ago By ABMN Staff
Aviso Wealth Management grew its stake in shares of Eli Lilly and Company ( NYSE:LLY – Free Report ) by 3.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,139 shares of the company’s stock after buying an additional 79 shares during the period.
Eli Lilly and Company accounts for about 1.1% of Aviso Wealth Management’s investment portfolio, making the stock its 16th largest position. Aviso Wealth Management’s holdings in Eli Lilly and Company were worth $1,936,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also recently modified their holdings of LLY. Vanguard Group Inc. lifted its stake in Eli Lilly and Company by 1.
6% in the 1st quarter. Vanguard Group Inc. now owns 72,745,011 shares of the company’s stock worth $56,592,709,000 after purchasing an additional 1,133,810 shares in the last quarter.
Capital World Investors increased its holdings in shares of Eli Lilly and Company by 0.3% in the fourth quarter. Capital World Investors now owns 26,949,773 shares of the company’s stock worth $15,709,466,000 after purchasing an additional 89,720 shares during the last quarter.
Capital Research Global Investors lifted its position in shares of Eli Lilly and Company by 6.0% in the first quarter. Capital Research Global Investors now owns 8,031,531 shares of the company’s stock worth $6,248,210,000 after buying an additional 453,939 shares in the last quarter.
Capital International Investors boosted its stake in Eli Lilly and Company by 5.1% during the first quarter. Capital International Investors now owns 6,972,393 shares of the company’s stock valued at $5,424,243,000 after buying an additional 335,560 shares during the last quarter.
Finally, Fisher Asset Management LLC grew its holdings in Eli Lilly and Company by 1.9% during the 4th quarter. Fisher Asset Management LLC now owns 4,542,089 shares of the company’s stock valued at $2,647,675,000 after buying an additional 85,015 shares in the last quarter.
Hedge funds and other institutional investors own 82.53% of the company’s stock. Eli Lilly and Company Price Performance LLY opened at $877.
79 on Friday. The business has a fifty day moving average of $896.10 and a 200 day moving average of $843.
52. The stock has a market cap of $834.26 billion, a P/E ratio of 129.
28, a PEG ratio of 2.78 and a beta of 0.42.
The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.
74. Eli Lilly and Company has a 52-week low of $516.57 and a 52-week high of $972.
53. Wall Street Analysts Forecast Growth Several analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft raised Eli Lilly and Company from a “hold” rating to a “buy” rating and upped their price objective for the stock from $725.
00 to $1,025.00 in a report on Monday, August 12th. Bank of America increased their price objective on shares of Eli Lilly and Company from $1,000.
00 to $1,125.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Morgan Stanley restated an “overweight” rating and issued a $1,106.
00 target price on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Wells Fargo & Company increased their price target on shares of Eli Lilly and Company from $875.00 to $1,000.
00 and gave the company an “overweight” rating in a report on Friday, August 9th. Finally, Evercore ISI raised Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock.
Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $977.35.
Check Out Our Latest Analysis on Eli Lilly and Company Insiders Place Their Bets In other news, major shareholder Lilly Endowment Inc sold 52,369 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, July 5th. The shares were sold at an average price of $915.18, for a total transaction of $47,927,061.
42. Following the completion of the sale, the insider now owns 97,247,403 shares of the company’s stock, valued at $88,998,878,277.54.
The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink . Insiders have sold 423,559 shares of company stock worth $393,136,808 in the last three months. Corporate insiders own 0.
13% of the company’s stock. Eli Lilly and Company Company Profile ( Free Report ) Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
See Also Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company ( NYSE:LLY – Free Report ). Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.
com's FREE daily email newsletter ..
